Caribou Biosciences(CRBU) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- $345.9 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q1 2026 -- "We continue to focus on advancing four clinical-stage programs, including the parallel development of ...